Association Between Symptom Severity and Medication Adherence in Adults with Bipolar Disorder Reporting Adherence Challenges.

Psychopharmacology bulletin Pub Date : 2024-07-08
Martha Sajatovic, Farren Briggs, Clara Adeniyi, Jacob Koopman, Jessica Black, Celeste Weise, Nicole Fiorelli, Joy Yala, Mohammad Lesanpezeshki, Douglas Einstadter, Jennifer B Levin
{"title":"Association Between Symptom Severity and Medication Adherence in Adults with Bipolar Disorder Reporting Adherence Challenges.","authors":"Martha Sajatovic, Farren Briggs, Clara Adeniyi, Jacob Koopman, Jessica Black, Celeste Weise, Nicole Fiorelli, Joy Yala, Mohammad Lesanpezeshki, Douglas Einstadter, Jennifer B Levin","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Given the importance of medication adherence among individuals with bipolar disorder (BD), this analysis from an ongoing randomized controlled trial (RCT) examined the relationship between BD symptoms, functioning and adherence in 69 poorly adherent adults with BD.</p><p><strong>Method: </strong>Study inclusion criteria included being ≥ 18 years old with BD Type 1 or 2, difficulties with medication adherence and actively symptomatic as measured by Brief Psychiatric Rating Scale (BPRS) score ≥ 36, Young Mania Rating Scale (YMRS) > 8 or Montgomery Asberg Depression Rating Scale (MADRS) > 8. Adherence was measured in 2 ways: 1) the self-reported Tablets Routine Questionnaire (TRQ) and 2) electronic pill container monitoring (eCap pillbox). BD symptoms and functioning were measured with the MADRS, YMRS, Clinical Global Impressions Scale (CGI), and Global Assessment of Functioning (GAF). Only screening and baseline data were examined.</p><p><strong>Results: </strong>Mean age was 42.32 (SD = 12.99) years, with 72.46% (n = 50) female and 43.48% (n = 30) non-white. Mean past 7-day percentage of days with missed BD medications using TRQ was 40.63% (SD = 32.61) and 30.30% (SD = 30.41) at screening and baseline, respectively. Baseline adherence using eCap was 42.16% (SD = 35.85) in those with available eCap data (n = 41). Worse adherence based on TRQ was significantly associated with higher MADRS (p = 0.04) and CGI (p = .03) but lower GAF (p = 0.02). eCAP measured adherence was not significantly associated with clinical variables.</p><p><strong>Conclusion: </strong>While depression and functioning were approximate markers of adherence, reliance on patient self-report or BD symptom presentation may give an incomplete picture of medication-taking behaviors.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"54 3","pages":"60-72"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11235580/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology bulletin","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Given the importance of medication adherence among individuals with bipolar disorder (BD), this analysis from an ongoing randomized controlled trial (RCT) examined the relationship between BD symptoms, functioning and adherence in 69 poorly adherent adults with BD.

Method: Study inclusion criteria included being ≥ 18 years old with BD Type 1 or 2, difficulties with medication adherence and actively symptomatic as measured by Brief Psychiatric Rating Scale (BPRS) score ≥ 36, Young Mania Rating Scale (YMRS) > 8 or Montgomery Asberg Depression Rating Scale (MADRS) > 8. Adherence was measured in 2 ways: 1) the self-reported Tablets Routine Questionnaire (TRQ) and 2) electronic pill container monitoring (eCap pillbox). BD symptoms and functioning were measured with the MADRS, YMRS, Clinical Global Impressions Scale (CGI), and Global Assessment of Functioning (GAF). Only screening and baseline data were examined.

Results: Mean age was 42.32 (SD = 12.99) years, with 72.46% (n = 50) female and 43.48% (n = 30) non-white. Mean past 7-day percentage of days with missed BD medications using TRQ was 40.63% (SD = 32.61) and 30.30% (SD = 30.41) at screening and baseline, respectively. Baseline adherence using eCap was 42.16% (SD = 35.85) in those with available eCap data (n = 41). Worse adherence based on TRQ was significantly associated with higher MADRS (p = 0.04) and CGI (p = .03) but lower GAF (p = 0.02). eCAP measured adherence was not significantly associated with clinical variables.

Conclusion: While depression and functioning were approximate markers of adherence, reliance on patient self-report or BD symptom presentation may give an incomplete picture of medication-taking behaviors.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
双相情感障碍成人患者的症状严重程度与坚持用药之间的关系(报告坚持用药挑战)。
背景:鉴于坚持服药在双相情感障碍(BD)患者中的重要性,这项正在进行的随机对照试验(RCT)分析研究了69名坚持服药较差的成人双相情感障碍患者的双相情感障碍症状、功能和坚持服药之间的关系:研究纳入标准包括:年龄≥ 18 岁,患有 BD 1 型或 2 型,难以坚持服药,且症状活跃(以简明精神病评定量表 (BPRS) 评分≥ 36 分、青年躁狂评定量表 (YMRS) > 8 分或蒙哥马利-阿斯伯格抑郁评定量表 (MADRS) > 8 分来衡量)。依从性通过两种方式进行测量:1)自我报告的片剂常规问卷(TRQ);2)电子药盒监测(eCap 药盒)。BD症状和功能通过MADRS、YMRS、临床整体印象量表(CGI)和整体功能评估(GAF)进行测量。仅对筛查和基线数据进行了研究:平均年龄为 42.32 (SD = 12.99)岁,72.46%(n = 50)为女性,43.48%(n = 30)为非白人。筛查和基线时,使用 TRQ 计算的过去 7 天漏服 BD 药物的平均天数百分比分别为 40.63%(SD = 32.61)和 30.30%(SD = 30.41)。在有 eCap 数据的患者(n = 41)中,使用 eCap 的基线依从性为 42.16%(SD = 35.85)。基于TRQ的较差依从性与较高的MADRS(p = 0.04)和CGI(p = 0.03)显著相关,但与较低的GAF(p = 0.02)显著相关:虽然抑郁和功能是依从性的近似标记,但依赖患者自我报告或 BD 症状表现可能无法全面反映服药行为。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Intravenous Magnesium for the Management of Chronic Pain:An Updated Review of the Literature. Metabolic Syndrome among Patients Taking Atypical Antipsychotics: A Comparative Cross-Sectional Study at Erada and Mental Health Complex in Taif, Saudi Arabia. Psychopharmacotherapy of Pica-How Much Do We Know? Serotonergic Drugs for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Review of Past Development, Pitfalls and Failures, and a Look to the Future. Stellate Ganglion Blocks for Post-Traumatic Stress Disorder: A Review of Mechanisms, Efficacy, and Complications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1